Table 3.
Combined analysis including all the sample sets (Helsinki, Tampere, Kuopio, and Oulu) in different subgroups, with the number of the FANCM c.5101C>T and c.5791C>T mutation carriers (combined) and non-carriers
Study cohort | OR | P | 95% CI | N Helsinki wt/mut | N Tampere wt/mut | N Oulu wt/mut | N Kuopio wt/mut | N Helsinki controls wt/mut | N Tampere controls wt/mut | N Oulu controls wt/mut | N Kuopio controls wt/mut |
---|---|---|---|---|---|---|---|---|---|---|---|
All BC | 1.86 | 0.0002 | 1.32–2.49 | 2285/81 | 656/35 | 1293/30 | 419/11 | 1234/21 | 782/21 | 498/12 | 157/1 |
Familial BC | 1.99 | 0.004 | 1.24–3.19 | 1020/38 | – | 148/5 | – | – | – | – | – |
Unselected BC | 1.77 | 0.0006 | 1.28–2.45 | 1652/58 | 656/35 | 1124/23 | 419/11 | – | – | – | – |
ER+ | 1.64 | 0.005 | 1.17–2.32 | 1721/55 | 480/22 | 426/8 | 292/8 | – | – | – | – |
ER- | 2.02 | 0.004 | 1.25–3.25 | 405/16 | 114/8 | 108/1 | 99/2 | – | – | – | – |
TNBC | 3.08 | 0.00007 | 1.77–5.35 | 130/10 | 60/5 | 68/1 | 58/2 | – | – | – | – |
BC breast cancer, ER estrogen receptor, TNBC triple-negative breast cancer, wt wild type, mut mutation carrier